Nicolas Favrolt

Nicolas Favrolt

Auto-generated profile, based on publicly available information

Nicolas Favrolt

Service de Pneumologie et Soins Intensifs Respiratoire, Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adultes de Dijon, réseau OrphaLung, Filière RespiFil, Centre Hospitalier Universitaire de Bourgogne, Dijon, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2024 in Chest
Verified
Journal Article
Open access
CPCamille Poisson
Camille Poisson
AHAlex Hlavaty
Alex Hlavaty
NFNicolas Favrolt
Nicolas Favrolt
MCMarie-Camille Chaumais
Marie-Camille Chaumais
JGJulien Grynblat
Julien Grynblat
David MontaniDavid Montani
David Montani
Trastuzumab-emtansine have been recently suspected to be associated with the development of pulmonary arterial hypertension (PAH). Is there an association between trastuzumab, trastuzumab-emtansine, or trastuzumab-deruxtecan and the development of PAH? Characteristics of incident PAH cases treated with trastuzumab, trastuzumab-emtansine or trastuzumab-deruxtecan, were analyzed from the French PH Registry, the VIGIAPATH program, concurrently with a pharmacovigilance disproportionality analysis using the WHO pharmacovigilance database using a broad definition of PH and a narrow definition of PAH. A signal of disproportionate reporting was deemed significant if the lower boundary of the 95% credibility interval (95%CI) of the Information Component (IC) was superior to 0. The variables were expressed as median (interquartile range). In the French PH Registry, we identified 8 incident cases of PAH after trastuzumab-emtansine exposure and none with trastuzumab alone or trastuzumab-deruxtecan. All cases occured in women (age of 56 (49-61) years) suffering from breast cancer. The delay between first exposure and PAH diagnosis was 43 (4.5-55) months. At diagnosis, 5 were in NYHA functional class III/IV with severe hemodynamic impairment (mean pulmonary artery pressure of 42 mmHg, cardiac index 2.51 L/min/m2, and pulmonary vascular resistance of 9.7 WU). Disproportionality analysis showed that only trastuzumab-emtansine demonstrated a significant signal of disproportionate reporting using both broad definition of PH (IC 1.46, 0.86-1.95) and narrow definition of PAH (IC 1.76, 0.83-2.46). Trastuzumab displayed a significant signal using only the broad definition of PH, while trastuzumab-deruxtecan was not associated with any significant signals of disproportionate reporting. Our results suggest that more patients exposed to trastuzumab-emtansine developed PH compared to trastuzumab alone. Further assessment of this safety signal and exploration of pathophysiological mechanisms is needed.